69 results about "Serum amyloid A" patented technology

The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.

Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.

The invention relates to a kit for quickly and quantificationally detecting serum amyloid A (SAA) by using an immunogold method. The kit includes lyophilized anti-SAA immunogold, a reaction plate, a sample diluent, a lyophilized colloidal gold complex solution, a scrubbing solution and a sealing solution. The preparation method comprises the following steps: (1) firstly preparing a conjugate of the colloidal gold and anti-SAA immunogold, and preparing lyophilized anti-SAA immunogold; and (2) preparing the sample diluent, the lyophilized colloidal gold complex solution, the scrubbing solution and the sealing solution according to the proportion, preparing the reaction plate, and assembling the prepared objects to a finished product to obtain the kit. By using the kit provided by the invention, a doctor can obtain an SAA measurement result on the spot when a person is ill so as to quickly judge the patient's condition, so that more targeted treatment can be effectively taken on the patient, healing time is shortened and medical cost is reduced. The kit provided by the invention has a good application prospect.

RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.

The invention provides a method of diagnosing tuberculosis (TB) in a test subject, said method comprising: (i) providing expression data of two or more markers in a subject, wherein at least two of said markers are selected from transthyretin, neopterin, C-reactive protein (CRP), serum amyloid A (SAA), serum albumin, apoliopoprotein-A1 (Apo-A1), apolipoprotein-A2 (Apo-A2), hemoglobin beta, haptoglobin protein, DEP domain protein, leucine-rich alpha-2-glycoprotein (A2GL) and hypothetical protein DFKZp667I032; and (ii) comparing said expression data to expression data of said marker from a group of control subjects, wherein said control subjects comprise patients suffering from inflammatory conditions other than TB, thereby determining whether or not said test subject has TB.

The invention relates to the technical field of fluorescence immunoassay in medical immunology, and in particular relates to a serumamyloid A (SAA) testing kit (fluorescence immunochromatographic method) and a manufacturing method. The kit is provided with a test paper card. The kit is characterized in that a PVC (Polyvinyl Chloride) plate, a sample pad, a conjugate pad, a nitrocellulose membrane and a water absorbing pad are sequentially arranged on the test paper card from bottom to top; a rare-earth Eu<3+> fluorescent microsphere marked serum amyloid A monoclonal antibody is adsorbed on the conjugate pad; the diameter of a rare-earth fluorescent microsphere is 200nm; the rare-earth fluorescent microsphere contains a rare-earth lanthanide element Eu<3+>; the rare-earth fluorescent microsphere is stable in a ground state and emits fluorescence of which the wavelength is 615nm under the stimulation action of laser of 337nm; and the monoclonal antibody is a monoclonal antibody which is purified and mixed, and comes from a monoclonal antibody cell strain for 2-6 different serum amyloid A epitopes. The kit has the advantages of being simple and convenient to operate, rapid in reaction, high in sensitivity, good in specificity and the like.

The invention discloses a latex-enhanced immune turbidimetric detection reagent for serum amyloid A (SAA‑Serum Amyloid A). The reagent is a single reagent, and the main component of the reagent is latex particles labeled with SAA antibody, and also includes buffer solution, surfactant, salt, stabilizer, suspending agent and preservative. The invention also discloses a method for using the reagent to detect the concentration of serum amyloid A (SAA) in blood samples by the principle of transmission or scattering turbidimetry. The invention adopts a single reagent, is simple to operate, does not need to be mixed, has high sensitivity, and has a wide linear range, and can directly measure various samples such as whole blood, serum, and plasma, and can be widely used in various transmission or scattering analyzers, including ordinary biochemical analyzers , specific protein analyzers, etc.

The invention provides a fluorescence immunosorbent assay kit for joint detection of SAA (Serum Amyloid A) and CRP (C-reactive protein) based on two-color quantum dots and a preparation method of thefluorescence immunosorbent assay kit, and belongs to the technical field of in vitro diagnostic detection. According to the fluorescence immunosorbent assay kit, the advantages of quantum dot multicolor marking and the characteristics of antibody antigen specific reaction are fully utilized; and two antibodies are coated onto the same enzyme coated plate hole to form two kinds of double antibody sandwich methods of coated antibody-to-be-tested antigen-quantum dot labeled antibodies, and a novel simple, sensitive and stable detection method of various markers is established. Compared with a traditional ELISA (Enzyme-linked immunosorbent assay) method, the method has the advantages that the use amount of detection samples is reduced and the detection time is shortened; in addition, the detection efficiency can be improved; the detection cost is favorably saved; and the medical cost is reduced.

Novel colostrum associated mammalian Serum Amyloid A (SAA) promoter sequences are disclosed. These promoters can be used in transgenic protocols for tissue specific expression and expression constructs, vectors and host cells are disclosed. Also the regulatory features of these promoters in colostrum associated SAA productions are exploited to treat disease states associated with or influenced by colostrum associated SAA production.

The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.

The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.

The invention discloses a test strip for immunochromatography-based rationed joint detection of C-reactive protein and serum amyloid A and a manufacture method of the test strip. The test strip comprises a clamp shell, a bottom plate, a sample pad, a fluorescence indicator combination pad, a nitrocellulose membrane and a water-absorbing pad, and is formed by sequentially adhering the sample pad, the fluorescence indicator combination pad, the nitrocellulose membrane and the water-absorbing pad to the bottom plate in a lap joint mode. The fluorescence indicator combination pad comprises streptavidin-labeled fluorescent protein, biotin-labeled C-reactive protein monoclonal antibodies, and biotin-labeled serum amyloid A monoclonal antibodies. Detection lines and quality control lines are arranged on the nitrocellulose membrane. The test strip and the manufacture method thereof have the advantages that the rapid rationed joint detection of the C-reactive protein/the serum amyloid A is realized through combination between a fluorescent protein indicator and a 'streptavidin-biotin amplification system'; detection time is shortened greatly, detection sensitivity is improved, and convenience and reliability are improved greatly through joint detection.

The invention discloses a serum amyloid A (SAA) protein and an encoding gene and an application thereof. The serum amyloid A protein is characterized in that a nucleotide sequence of the serum amyloid A protein is as showed in the 148-567th basic groups of SEQ ID NO.1, and the amino acid sequence of the serum amyloid A protein is as shown in SEQ ID NO.2. The gene is firstly discovered in a mollusk, and at present, the gene is discovered in vertebrates and is only discovered in an echinodermata in invertebrates. The quantitative PCR experiment proves that the oyster SAA is remarkably up-regulated after bacterial infection and is similar to a mammal, and thus the gene is utilized as a gold standard for detecting the oyster physical condition. The gene can monitor the physical condition of the oyster at any time by detection, a positive accurate caution signal is provided for the oyster disease prevention, and the expansion of a disaster is prevented. The application of the technology has the advantages that the germplasm innovation capability of the cultivated shellfish is further improved, and the efficient sustainable development of an industry is supported.

The invention discloses an SAA monoclonal antibody 03-7-3, the heavy chain of the SAA monoclonal antibody 03-7-3 is IgG1, the light chain is k, and the amino acid sequences of the variable regions ofthe heavy chain and the light chain are respectively shown as SEQ ID NO. 3 and SEQ ID NO. 4. The SAA monoclonal antibody 03-7-3 disclosed by the invention can specifically identify disease-related SAA-ApoA1-HDL complex and SAA proteins, and on the basis of the SAA monoclonal antibody 03-7-3, an assay method for the SAA-ApoA1-HDL complex and the SAA proteins is established. The SAA-ApoA1-HDL complex is significantly associated with liver cirrhosis, and is a potential risk factor for the liver cirrhosis; and the concentration of the SAA proteins is significantly associated with the liver cirrhosis due to hepatitis B and liver cancer, and is a potential risk factor for the liver cirrhosis due to hepatitis B and the liver cancer. Therefore, the SAA monoclonal antibody 03-7-3 disclosed by the invention has important clinical value for the prediction of the potential risk of the liver cirrhosis and the liver cancer and the development of diagnostic markers for the diseases.

The invention provides a detection device for simultaneously and quantitatively detecting SAA/PCT/CRP. The detection device for simultaneously, rapidly and quantitatively detecting SAA/PCT/CRP is composed of human serum amyloid A (SAA) test paper, human procalcitonin (PCT) test paper, C-reactive protein (CRP) test paper, a triplicate card case and an immunochromatography interpretation result recorder carrying a corresponding judgment method and a standard curve, wherein the human serum amyloid A (SAA) test paper, the human procalcitonin (PCT) test paper and the C-reactive protein (CRP) test paper are independent. The detection device is suitable for on-site detection, a detection method is easy, convenient and stable, the situation that a large number of blood samples are extracted is not needed, medical cost is reduced, sensitivity is high, and SAA/PCT/CRP can be simultaneously, rapidly and quantitatively detected.